Optimi Health Secures Ibogaine Supply

Optimi Health, a pharmaceutical manufacturer, has announced it secured naturally derived ibogaine and will begin developing finished drug products this summer at its GMP facility in British Columbia, Canada. This initiative follows a U.S. Executive Order on April 18, 2026, which prioritized ibogaine compounds for accelerated United States — Food and Drug Administration review and expanded patient access, also directing federal funding to match state investments in psychedelic research, including a $50 million program in United States — Texas. Ibogaine is being investigated for treating PTSD, opioid use disorder, and traumatic brain injury. Canada's regulatory environment, where ibogaine is not a controlled substance under the Controlled Drugs and Substances Act but regulated under the Food and Drugs Act by Canada — Health Canada, provides Optimi Health with an advantageous position for compliant manufacturing and supply.